Prothena Co. PLC to Post FY2021 Earnings of ($1.08) Per Share, Oppenheimer Forecasts (NASDAQ:PRTA)
Prothena Co. PLC (NASDAQ:PRTA) – Analysts at Oppenheimer lifted their FY2021 EPS estimates for shares of Prothena in a report released on Wednesday, July 8th. Oppenheimer analyst J. Olson now expects that the biotechnology company will post earnings per share of ($1.08) for the year, up from their prior estimate of ($1.44). Oppenheimer currently has a “Outperform” rating and a $16.00 target price on the stock. Oppenheimer also issued estimates for Prothena’s FY2022 earnings at ($2.44) EPS, FY2023 earnings at ($0.56) EPS and FY2024 earnings at ($1.46) EPS.
PRTA has been the subject of several other reports. Zacks Investment Research raised shares of Prothena from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Saturday, June 6th. Nomura reiterated a “buy” rating and issued a $19.00 price target on shares of Prothena in a research note on Sunday, May 10th. ValuEngine downgraded Prothena from a “hold” rating to a “sell” rating in a research note on Wednesday, April 1st. Finally, BidaskClub lowered shares of Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $15.80.
Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.02). The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.23 million. Prothena had a negative net margin of 10,452.67% and a negative return on equity of 28.71%.
Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp boosted its holdings in shares of Prothena by 1.5% during the 1st quarter. State Street Corp now owns 1,053,448 shares of the biotechnology company’s stock worth $11,272,000 after purchasing an additional 15,176 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Prothena by 3.7% in the first quarter. Geode Capital Management LLC now owns 590,126 shares of the biotechnology company’s stock valued at $6,314,000 after purchasing an additional 20,791 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Prothena by 34.5% during the 1st quarter. Nuveen Asset Management LLC now owns 512,306 shares of the biotechnology company’s stock worth $5,482,000 after buying an additional 131,483 shares during the last quarter. Rock Springs Capital Management LP acquired a new stake in Prothena during the first quarter worth $5,350,000. Finally, Goldman Sachs Group Inc. raised its holdings in Prothena by 30.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 469,225 shares of the biotechnology company’s stock valued at $7,427,000 after buying an additional 109,645 shares during the period. Institutional investors and hedge funds own 93.08% of the company’s stock.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Featured Article: How does a security become overbought?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.